| Autor: |
Iacovelli, Roberto, Astore, Serena, Ciccarese, Chiara, Cannella, Maria Antonella, Bove, Pierluigi, Iacovelli, Valerio, Tortora, Giampaolo |
| Předmět: |
|
| Zdroj: |
Expert Review of Anticancer Therapy; Nov 2021, Vol. 21 Issue 11, p1207-1210, 4p |
| Abstrakt: |
Background: Prostate cancer (PC) is a heterogeneous disease that requires a personalized treatment approach for proper patient management.Aim: We analyzed a selected overview of the most important news recently presented at the 2021 ASCO genitourinary cancer symposium.Results: In particular, we focused on the identification of predictive biomarkers as potential targets for therapy. Molecular signatures of increased T cell activity, proliferation, and hormone dependence were associated with greater probability of response to apalutamide in non-metastatic CRPC. Pathogenic variants of DDR genes mutations detected with circulating tumor DNA (ctDNA) analysis, which had a high concordance with tumor tissue analysis, might represent a useful way for selecting mutated patients for poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors therapy. Loss of PTEN could be a target for ipatasertib (a pan-AKT inhibitor) associated with abiraterone in mCRPC patients.Conclusions: The 2021 ASCO Genitourinary Cancers Symposium significantly contributed to the complex research goal of intimately understanding PC carcinogenesis with the ultimate aim of improving patient outcomes. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
